ClinicalTrials.gg
CompletedNCT02487407ALSUpdated Nov 28, 2017

Effects of ODM-109 on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis

A Phase 2 interventional study of ODM-109 and Placebo for ODM-109 in Amyotrophic Lateral Sclerosis, sponsored by Orion Corporation, Orion Pharma. Completed at 11 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-11-28.

Sponsored by Orion Corporation, Orion Pharma · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 70 studies in Amyotrophic Lateral Sclerosis with a site in United Kingdom — 15 open to participants now, 22 under way, 6 of them phase 3. Amyotrophic Lateral Sclerosis · United Kingdom.

Enrollment
40th of 55
66 · median 227
Started
2015
with 4 others
Phase 2
14 of 70
none open now
Registered
15th of 70
by date
Lead sponsor
3 of 70
Orion Corporation, Orion Pharma

Among the 70 studies in Amyotrophic Lateral Sclerosis with a site in United Kingdom, this one is the 40th largest by enrollment of the 55 interventional ones that give a count, is one of 5 that started in 2015, is one of 14 in phase 2, and was the 15th registered.

Amyotrophic Lateral Sclerosis

981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

15 of the 70 studies in Amyotrophic Lateral Sclerosis with a site in United Kingdom are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies in Amyotrophic Lateral Sclerosis with a site in United Kingdom, or all of them as a file.
02

Study summary

In the double-blind, cross-over part of the study, ODM-109 capsules and placebo capsules for ODM-109 will be administered for 2 weeks separated by a 19-23 days wash-out period. During each treatment period of the double-blind cross-over part, there will be a baseline visit (day 1) and 2 visits (5 ± 2 and 14 ± 2 days) after the start of study treatment. After completing the 3rd treatment period, the subjects will continue in the open-label follow-up part for 6 months. During the open-label follow-up, visits will be at 1, 3 and 6 months. An end-of-study visit will take place 14-25 days after the last study treatment administration for each subject. The study duration will be about 13-14 weeks for the double-blind cross-over part, and about 9-10 months for the entire study including the 6 months open-label follow-up.

The number of randomised study subjects is planned to be approximately 54 in cross-over comparison. The maximum number of subjects will not exceed 70.

Primary objective is to investigate the efficacy of oral ODM-109 on respiratory function in patients with amyotrophic lateral sclerosis (ALS).

03

Conditions studied

  • Amyotrophic Lateral Sclerosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written (IC) for participation in the study will be obtained from the subject (or from the subject's next of kin, caregiver, or other legally acceptable representative in case the study subject him/herself cannot sign the IC due to severe muscle weakness).
  • Age of at least 18 years.
  • Male or female subjects with diagnosis of laboratory supported probable, probable or definite ALS according to El Escorial revised criteria (Brooks BR et al., 2000). Full electromyogram (EMG) report available compatible with ALS according to an experienced neurophysiologist.
  • Ability to swallow the study treatment capsules.
  • An upright (sitting position) SVC between 60-90% of the predicted value for age, height and sex at screening visit.
  • Normal oxygen saturation during daytime (measure of ≥ 95% when steady state has been reached with a reliable read) in sitting position measured by pulse oximetry.
  • Disease duration from symptom onset (defined by first muscle weakness or dysarthria) of 12-48 months.
  • Using riluzole. The dose must have been stable for at least 4 weeks prior to screening at a dose of 50 mg b.i.d.

Exclusion criteria

Exclusion Criteria:

  • Subject in whom other causes of neuromuscular weakness have not been excluded.
  • Subject with a diagnosis of another neurodegenerative disease (e.g. Parkinson's or Alzheimer's disease).
  • Assisted ventilation or gastrostomy of any type during the preceding 3 months prior to screening or predicted to be required within the randomised, double-blind cross-over part of the study.
  • Recorded diagnosis or evidence of major psychiatric diagnosis, significant cognitive impairment or clinically evident dementia.
  • Any major surgery within 1 month before the screening visit or patients who are scheduled for any major surgery during the planned study period.
  • Potassium \< 3.7 mmol/l or > 5.5 mmol/l at screening.
  • Creatinine > 170 μmol/l at screening or on dialysis.
  • Blood \< 10 g/dl at screening.
  • hepatic impairment at the discretion of the investigator.
  • Women of reproductive age without a negative pregnancy test and without a commitment to using an acceptable method of barrier or hormonal (e.g. condoms, diaphragms, oral contraceptives and long acting progestin agents), if sexually active during the study, and for 1 month after the last dose of the study treatment. Women who are (1 year since last menstrual cycle), surgically sterilised or who have undergone a hysterectomy are considered not to be reproductive and can be included.
  • Known to levosimendan.
  • Administration of levosimendan within 30 days prior to screening visit.
  • Patients with history of botulinum toxin treatment for any reason.
  • Patients with known history of infection.
  • History of significant arrhythmias or other cardiac events
  • Any other clinically significant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, neurological or psychiatric disorder or any other major concurrent illness that in the opinion of the investigator could interfere with the interpretation of the study results or constitute a health risk for the subject if he/she took part in the study.
  • Blood donation or loss of significant amount of blood within 60 days prior to screening.
  • Participation in a clinical trial with any experimental treatment within 30 days prior to the screening visit or previous participation in the present study.
  • Any other condition that in the opinion of the investigator could interfere with the interpretation of the study results or constitute a health risk for the subject if he/she took part in the study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    ODM-109

    ODM-109 capsules for oral administration

    Drug: ODM-109 · Drug: Placebo for ODM-109

  • Placebo comparator
    Placebo for ODM-109

    Placebo ODM-109 capsules for oral administration

    Drug: ODM-109 · Drug: Placebo for ODM-109

Interventions

  • DrugSimendanStudies of SimendanSimendan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    ODM-109 1 mg capsule for oral administration.

    Also known as: Levosimendan

  • DrugPlacebo for ODM-109

    Placebo capsule for oral administration.

    Also known as: Placebo for Levosimendan

06

What researchers measure

Primary outcomes

  1. Slow vital capacity SVC

    Pulmonary assessment

    Time frame: 9 months

Secondary outcomes

  1. Hand grip strength and submaximal hand grip strength endurance

    Assessment

    Time frame: 3 months

  2. Changes in subject's clinical condition (relative to the baseline/day 1 of the given treatment period) will be assessed using the Clinical Global Impression of Change (CGI-C)

    Scales

    Time frame: 3 months

  3. Quality of life

    Questionnaire

    Time frame: 9 months

  4. Revised ALS Functional Rating Scale ALSFRS-R

    Scale

    Time frame: 9 months

  5. Oxygen saturation

    Assessment

    Time frame: 9 months

  6. The concentrations of ODM-109, OR-1855 and OR-1896

    Pharmacokinetics Blood samples.

    Time frame: 3 months

  7. Determination of subject's acetylation status

    Pharmacogenomics Blood samples.

    Time frame: 1 day (once at baseline)

  8. Sniff nasal pressure SNP

    SNP will be assessed in sitting position. SNP will be performed for 10 times. The highest value (cmH2O) measured will be the SNP variable.

    Time frame: 9 months

  9. Fatigue assessment

    Visual analogue Scale VAS

    Time frame: 3 months

07

Study locations

11 sites
  • Charite Universitatsmedizin Berlin
    Berlin, Germany
  • Medical School Hannover
    Hannover, Germany
  • University Clinical Jena
    Jena, Germany
  • University Hospital of Ulm
    Ulm, Germany
  • Beaumont Hospital
    Dublin, Ireland
  • University Medical Centre Utrecht
    Utrecht, Netherlands
  • Royal Sussex County Hospital
    Brighton, United Kingdom
  • The Walton Centre
    Liverpool, United Kingdom
  • London Kings College Hospital
    London, United Kingdom
  • Royal London Hospital
    London, United Kingdom
  • University of Sheffield
    Sheffield, United Kingdom
08

References and documents

Publications

  • Al-Chalabi A, Shaw P, Leigh PN, van den Berg L, Hardiman O, Ludolph A, Aho VV, Sarapohja T, Kuoppamaki M. Oral levosimendan in amyotrophic lateral sclerosis: a phase II multicentre, randomised, double-blind, placebo-controlled trial. J Neurol Neurosurg Psychiatry. 2019 Oct;90(10):1165-1170. doi: 10.1136/jnnp-2018-320288. Epub 2019 Jul 17. PubMed 31315908 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2015 to primary completion in May 2017, 22 months.

Of 36 industry-sponsored phase 2 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 35. This study's 22 months is close to that.

Counting every sponsor, half of 73 studies reached it within 24 months; a quarter within 16 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2015
First posted
Jul 1, 2015
StartActual
Jul 2015
Primary completionActual
May 2017
CompletionActual
Jun 2017
Last update
Nov 28, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02487407
Responsible party
Sponsor
First posted
Jul 1, 2015
Start date
Jul 2015
Primary completion
May 2017
Completion
Jun 2017
Last update
Nov 28, 2017

Study contacts

Merja Mäkitalo, CSD
study director · Finland

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Simendan

Start the discussion